Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients

Abstract

BackgroundTreating elderly breast cancer patients remains a challenge but the increasing availability of immunotherapeutic approaches instills optimism that these tumours may also be susceptible to immune control. Because aging leads to a number of alterations in the immune system (“immunosenescence”) reflecting potential exhaustion which could compromise immunomodulatory antibody therapy, here we have assessed the immunocompetence of elderly breast cancer patients compared with a group of younger patients, and related this to the 5-year survival of the former.MethodsT-cell responses to Her-2 peptide pools in vitro were assessed by analyzing pro- and anti-inflammatory cytokine production by CD4+ and CD8+ T-cells in 40 elderly and 35 younger breast cancer patients.ResultsThe proportions of older and younger patients whose peripheral T-cells responded to Her-2 peptides in vitro were found to be similar, although a significantly higher fraction of younger patients possessed IL-2-producing CD4+ Her-2-reactive T-cells than in the elderly (p = 0.03). However, IL-2 production did not impart a survival benefit to the latter. In contrast, there was a survival benefit of possessing Her-2-reactive CD8+ T-cells, but this was abrogated in patients if they also had CD4+ Her-2-responsive T-cells that producedIL-5 and/or IL-17 (p = 0.01). This resulted in a 5-yr survival rate of only 29 % compared to 76 % for patients whose her-2-reactive CD4+ T-cells did not produceIL-5 and/or IL-17. Additionally, patients whose CD8+ T-cells produced TNF had a significantly better survival than those that did not (93 % compared to 52 %, p = 0.01), whereas no survival benefit was attributable to possessing IFN-γ-producing cells.ConclusionsElderly breast cancer patients appear perfectly immunocompetent to respond to Her-2 peptide pools in vitro, with response patterns very similar to younger patients. The nature of this response is associated with 5-year survival of these elderly patients, suggesting that boosting anti-tumor responses and modulating the nature of the T-cell response is likely to be effective even in potentially immunosenescent elderly breast cancer patients, and might be useful for predicting which patients are most likely to benefit from such treatments.Electronic supplementary materialThe online version of this article (doi:10.1186/s40425-015-0090-0) contains supplementary material, which is available to authorized users.

Immune correlates of clinical outcome in melanoma

“…This was shown to be the case in breast cancer (and so not limited to one potentially unusual tumour type) and also in older patients (and so not negatively affected by immune ageing). These results document that such combined ‘immune signatures’ do not necessarily apply solely to one type of cancer that might not have been representative, and also that the immune system of older patients (> 80 years of age) was functionally intact, at least in this respect . This is important, given the common perception that ageing of the immune system (‘immunosenescence’) contributes not only to decreased protection against infectious disease, but also cancer, as cited in many reviews (e.g.…”

Effect of Fu-Zheng-Xiao-Liu Granules on Expression of Human Epidermal Growth Factor Receptor 2 (HER-2) and Proliferation and Apoptosis of Breast Cancer Cell Line SKBR-3

“…HER-2 overexpression has become an important marker of poor prognosis in breast cancer patients [9–16]. Our group previously found that the Fu-Zheng-Xiao-Liu granules could inhibit the proliferation of drug-resistant MCF-7 cells and enhance the sensitivity of drug-resistant MCF-7 cells to a combination of chemotherapy drugs.…”

Does Regular Exercise Counter T Cell Immunosenescence Reducing the Risk of Developing Cancer and Promoting Successful Treatment of Malignancies?

“…In support, it has been demonstrated that IL-15 enhances the activity of tumour-specific T cells via delaying or reversing senescence, as shown by lower expression of p 16 INK4a among other markers of senescence [ 179 ]. Indeed, recent research has indicated that the capacity of peripheral blood T cells to recognise and respond to tumour-associated antigens is a predictor of survival in several malignancies, including breast cancer [ 180 , 181 ], colon cancer [ 182 ], melanoma [ 183 , 184 ], and hepatocellular carcinoma [ 185 ].…”